Partner Doses First Patient in Phase 2 IgAN Trial
CLYM has more than doubled off its 52-week low of $1.54.
Summary
Climb Bio's partner Beijing Mabworks Biotech has dosed the first patient in a Phase 2 trial of budoprutug for IgA nephropathy in China, expanding the drug's clinical development.
Key Events · Product Development and Regulatory · CLYM
-
Phase 2 IgAN Trial Initiated
Beijing Mabworks Biotech has dosed the first patient with IgA nephropathy in a Phase 2 trial in China, conducted in collaboration with Climb Bio.
-
Pipeline Expansion
Budoprutug's clinical development now includes IgA nephropathy in addition to the previously reported primary ITP indication.
-
Collaboration Milestone
The dosing marks a concrete step in the Climb Bio–Beijing Mabworks collaboration, though no efficacy data is yet available.
Analysis · CLYM · Life Sciences
Beijing Mabworks Biotech has dosed the first patient in a Phase 2 trial of budoprutug for IgA nephropathy in China. This milestone broadens the drug's clinical footprint beyond the previously reported primary ITP indication and represents a concrete step forward in the collaboration. For a company trading near its 52-week high, the news reinforces the pipeline narrative, though efficacy data is still pending.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1963 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.14%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLYM was trading at $14.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $846M. The 52-week trading range was $1.54 to $15.21. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.